Literature DB >> 1526082

Ethylmorphine O-deethylation cosegregates with the debrisoquin genetic metabolic polymorphism.

A Rane1, A R Modiri, E Gerdin.   

Abstract

The single oral dose kinetics of ethylmorphine and its fractional metabolic clearance by O-dealkylation and N-dealkylation was investigated in five extensive and four poor metabolizers of dextromethorphan. In addition, the urinary metabolic ratios for these pathways (MRO and MRN, respectively) were investigated in a larger group of 27 extensive metabolizers and six poor metabolizers. The mean values for the fractional metabolic clearance by O-dealkylation and the MRO differed significantly between the poor metabolizers and extensive metabolizers without overlap between the values of either of these parameters in the two groups of subjects. In contrast, the corresponding parameters for the N-demethylation did not differ between poor metabolizers and extensive metabolizers. The area under the plasma concentration versus time curve was significantly higher (about three times higher) in the poor metabolizers compared with the extensive metabolizers (p = 0.004). Our data suggest that ethylmorphine is O-deethylated by the cytochrome P4502D6 isozyme inasmuch as both the fractional metabolic clearance by O-dealkylation and the MRO were found to cosegregate with the phenotype for the O-demethylation of dextromethorphan in our group of subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1526082     DOI: 10.1038/clpt.1992.139

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

1.  Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism.

Authors:  Z Liu; O Mortimer; C A Smith; C R Wolf; A Rane
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

2.  Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose.

Authors:  T A Aasmundstad; B Q Xu; I Johansson; A Ripel; A Bjørneboe; A S Christophersen; E Bodd; J Mørland
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.